Wolfe Research initiated coverage of MetLife with a rating of Outperform and set a new price target of $95.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/16/2025 | $95.00 | Outperform | Wolfe Research |
| 1/23/2025 | $97.00 | Market Perform | BMO Capital Markets |
| 10/9/2024 | $97.00 | Buy | TD Cowen |
| 9/5/2024 | $91.00 | Overweight | Barclays |
| 1/8/2024 | $80.00 | Neutral → Buy | Goldman |
| 11/17/2023 | $71.00 | Overweight | Barclays |
| 10/5/2023 | $71.00 | Hold | Deutsche Bank |
| 9/14/2023 | $58.00 → $72.00 | Hold → Buy | Jefferies |
Wolfe Research initiated coverage of MetLife with a rating of Outperform and set a new price target of $95.00
BMO Capital Markets initiated coverage of MetLife with a rating of Market Perform and set a new price target of $97.00
TD Cowen initiated coverage of MetLife with a rating of Buy and set a new price target of $97.00
Lowe's Companies recognized as a leader in corporate disclosure transparency. Lowe's Companies, Dow, American Express, ConocoPhillips, and AIG secured top honors in the 2025 U.S. Transparency Awards announced today by Labrador Transparency, a leading global communications firm specializing in transparent corporate disclosure documents. The rankings are determined through a rigorous evaluation of corporate disclosure documents and celebrate companies dedicated to building investor and stakeholder trust through clear, concise, and effective communication. "Companies that commit to openness see rewards in the form of higher investor engagement, stronger alliances, and improved voting resul
MetLife, Inc. (NYSE:MET) today announced that it has received notice of an unsolicited mini-tender offer by Potemkin Limited ("Potemkin") to purchase up to 10,000 shares of MetLife, Inc. common stock from MetLife shareholders. The offer is for approximately 0.00002 percent of MetLife's shares of common stock outstanding as of August 31, 2025. Potemkin's offer price of $53.00 per share is approximately 34.42 percent lower than the $80.82 closing price of MetLife common stock on September 12, 2025. MetLife does not endorse Potemkin's unsolicited mini-tender offer and recommends that shareholders do not tender their shares in response to Potemkin's offer because the offer is at a price that
Through a strategic collaboration with Private Health Management, new offering provides individuals with expert-guided cancer education and financial support MetLife has introduced a new Cancer Support benefit to help employees with personalized advice and attention from diagnosis to treatment and through recovery. Through a strategic relationship with Private Health Management, a leader in complex care navigation, MetLife will expand its Critical Illness Insurance offering to provide a more robust cancer benefit, including access to top oncology specialists, tech-enabled and expert-led coordination, and patient counseling – all of which help to provide a clearer path forward for patients
Acquisition includes high yield, strategic fixed income and small-cap equity teams MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE:MET), today announced that it has reached a definitive agreement to acquire three investment teams and assets managed by Mesirow, an independent, employee-owned financial services firm. MIM is acquiring the high yield and bank loan, strategic fixed income and small-cap equity teams and certain related investment products. Under the terms of the transaction, about $6 billion of assets managed by the acquired teams will transfer to MIM, subject to customary approvals and consents. The acquisition is consi
MetLife Investment Management (MIM), the institutional asset management business of MetLife, Inc. (NYSE:MET), today announced that it has appointed Kerry O'Brien as global head of Insurance Asset Management and Liability Solutions. She will be responsible for the execution of investment strategies for the MetLife general account, helping drive growth in MIM's third-party insurance client channel as well as working with teams to drive liability solutions across other client segments. O'Brien will lead a team with an insurance investing heritage of nearly 150 years and an active role in managing MetLife's $414.1 billion general account as well as assets for third-party insurance clients. Sh
Combining the medical and ancillary strengths of two leading global carriers into a single solution -- Globaline™ MetLife and GeoBlue, the international solution for the Blue Cross® Blue Shield® companies, announced today they will offer a full suite of expatriate benefit products in a best-in-class single solution, Globaline™. Globaline™ brings together health coverage and services from GeoBlue – including medical, dental, vision, prescription, wellness, international employee assistance program and political and natural disaster assistance – and life, accidental death & dismemberment and long term disability coverage from MetLife Worldwide Benefits, including value-added services, such
4 - METLIFE INC (0001099219) (Issuer)
4 - METLIFE INC (0001099219) (Issuer)
4 - METLIFE INC (0001099219) (Issuer)
4 - METLIFE INC (0001099219) (Issuer)
8-K - METLIFE INC (0001099219) (Filer)
Full Redemption of 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G MetLife, Inc. (NYSE:MET) today announced that it will redeem all outstanding shares of its 3.850% Fixed Rate Reset Non-Cumulative Preferred Stock, Series G, liquidation preference of $1,000 per share ("Series G Preferred Stock"), at a redemption price of $1,000 per share of Series G Preferred Stock. All outstanding shares of Series G Preferred Stock will be redeemed on the dividend payment date of September 15, 2025. Regular dividends on the outstanding shares of Series G Preferred Stock of $19.250 per share will be paid separately on September 15, 2025, to holders of record as of the close of business o
MetLife, Inc. (NYSE:MET) today announced that it has declared the following preferred stock dividends: Quarterly dividend of $0.35263005 per share on the company's floating rate non-cumulative preferred stock, Series A, with a liquidation preference of $25 per share (NYSE:MET). Semi-annual dividend of $29.375 per share on the company's 5.875% fixed-to-floating rate non-cumulative preferred stock, Series D, with a liquidation preference of $1,000 per share. Quarterly dividend of $351.5625 per share on the company's 5.625% non-cumulative preferred stock, Series E, with a liquidation preference of $25,000 per share, represented by depositary shares each representing 1/1,000th interest
MetLife, Inc. (NYSE:MET) today announced its second quarter 2025 results. Earnings Return Per Share on Equity (ROE) 2Q 2025 2Q 2025 Net Income $1.03 ROE 11.7% Adjusted Earnings $2.02 Adjusted ROE 14.6% Net income was $698 million. Adjusted earnings declined to $1.4 billion, due to less favorable underwriting and lower investment margins, partially offset by volume growth and favorable expense margins. Premiums, fees and other revenues (PFOs) were $12.7 billion. Adjusted
SC 13D/A - METLIFE INC (0001099219) (Subject)
SC 13D/A - METLIFE INC (0001099219) (Subject)
SC 13D/A - METLIFE INC (0001099219) (Subject)